Depression at Treatment Initiation Predicts HIV Antiretroviral Adherence in Uganda
ResearchPosted on rand.org Dec 8, 2016Published in: Journal of the International Association of Providers of AIDS Care, 2016
Presence of depression at the start of HIV antiretroviral therapy can affect whether patients take their medications, which suggests that screening and early treatment could help boost rates of medication adherence.
ResearchPosted on rand.org Dec 8, 2016Published in: Journal of the International Association of Providers of AIDS Care, 2016
We examined the relationship between depression (symptom type, diagnostic severity, and change over time) and adherence to HIV antiretroviral therapy (ART) with data from 3 longitudinal studies (N = 1021) of patients starting ART in Uganda. The Patient Health Questionnaire was used to assess depressive symptoms (total score; somatic and cognitive subscales) and categorize severity level. At baseline, 9% had major depression and 30% had minor depression; 82% were adherent (reported no missed ART doses in the past 7 days) at month 6 and 85% at month 12. Controlling for demographic and medical covariates, multivariate random-effects logistic regression models revealed that change in depression was not related to adherence; however, baseline total depression symptoms and cognitive symptoms in particular as well as major and minor depression were significant predictors of adherence. These findings highlight the need for early identification and aggressive treatment of depression to optimize ART adherence.
This publication is part of the RAND external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.
RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.